Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.48 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27570606 | 0.94 | HRH3 (0.50) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL380954 | 0.88 | CNR1 (0.50) | NOS1NOS2NOS3TAAR1KIF11 | |
| SCHEMBL920929 | 0.87 | LPL (0.49) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL3057497 | 0.86 | TAAR1 (0.63) | LOXL2NOS1SMN1; SMN2TAAR1KIF11 | |
| Propylamine SCHEMBL4356386 | 0.86 | LOXL2 (0.55) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL28208656 | 0.85 | LOXL2 (0.60) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL920969 | 0.85 | LPL (0.56) | TLR8 | |
| SCHEMBL15345501 | 0.84 | LPL (0.57) | TLR8 | |
| SCHEMBL15345523 | 0.84 | LPL (0.57) | TLR8 | |
| SCHEMBL921341 | 0.84 | LPL (0.57) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3337481-B1 | QUINOLINE-2-AMINE DERIVATIVES AS HUMAN TLR8-SELECTIVE AGONISTS FOR INCREASING IMMUNE RESPONSE | UNIV KANSAS (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019195720-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| CN-103947031-B | Organic electrolyte and organic electrolyte secondary battery | 吉坤日矿日石能源株式会社 | 2017-07-11 | — | — | CN | disclosed |
| CN-104025364-B | Organic bath and organic bath accumulator | 吉坤日矿日石能源株式会社 | 2017-03-08 | — | — | CN | disclosed |
| WO-2017034986-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-2657214-B1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| CN-1054803-C | Polycarbonic acid ester resin layered products absorbing near-infrared and formed products made of same | DAICEL CHEM (JP) | 2000-07-26 | — | — | CN | disclosed |
| CN-1094354-A | Polycarbonate-based resin laminate of absorption near infrared ray and formed body thereof | DAICEL CHEM (JP) | 1994-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | LOXL2 2209/4885PNMT 1739/4885ENPP2 524/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | LOXL2 2209/4885PNMT 1739/4885ENPP2 524/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | LOXL2 3474/4885PNMT 2144/4885ENPP2 2098/4885 |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | LOXL2 2014/4885PNMT 4710/4885ENPP2 714/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | LOXL2 1785/4885PNMT 3530/4885ENPP2 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.